HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Viridian Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($1.13) per share for the quarter, down from their previous estimate of ($1.09). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2026 earnings at ($1.21) EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($2.87) EPS, FY2029 earnings at ($1.49) EPS and FY2030 earnings at $0.40 EPS.

Several other research firms have also commented on VRDN. Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a report on Wednesday, May 13th. Wells Fargo & Company upgraded shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a report on Friday, May 15th. Finally, Wall Street Zen downgraded Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $38.93.

Viridian Therapeutics Stock Down 0.4%

Shares of NASDAQ:VRDN opened at $22.97 on Monday. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -6.82 and a beta of 0.91. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The company’s fifty day moving average is $18.65 and its two-hundred day moving average is $21.45. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative return on equity of 76.65% and a negative net margin of 505.86%.

Hedge Funds Weigh In On Viridian Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in Viridian Therapeutics in the 1st quarter valued at approximately $34,000. ANTIPODES PARTNERS Ltd acquired a new position in Viridian Therapeutics during the 4th quarter worth $36,000. State of Wyoming acquired a new position in Viridian Therapeutics during the 2nd quarter worth $43,000. Larson Financial Group LLC bought a new position in shares of Viridian Therapeutics in the third quarter worth $52,000. Finally, US Bancorp DE grew its stake in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.